insights_auto
Why is ALCOX up 4.75%?
Dive Deeperchevron_right
ALCOX:EPA
NicOx SA
€0.31
arrow_upward
+4.75%(+0.014) 1D
Oct 9, 5:35:31 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALCOX...
Open
€0.31
High
€0.31
Low
€0.30
Mkt. cap
26.44M
Avg. vol.
170.04K
Volume
90.64K
52-wk high
€0.57
52-wk low
€0.28
EPS
-€0.03
Shares outstanding
97.55M
No. of employees
10
Open
€0.31
High
€0.31
Low
€0.30
Mkt. cap
26.44M
Avg. vol.
170.04K
Volume
90.64K
52-wk high
€0.57
52-wk low
€0.28
EPS
-€0.03
Shares outstanding
97.55M
No. of employees
10
News stories
From web sources and news partners
bloomingbit
·
10 minutes ago
Direxion Launches S&P 500 ETF With Managed Futures Overlay for Wary Retail Investors
Mitrade
·
54 minutes ago
Current S&P 500 Bull Market Turns 4 Monday and History Suggests More to Come
FOREX.com
·
1 day ago
S&P500 Forecast: SPX falls from record highs ahead of Fed minutes
BigGo Finance
·
4 hours ago
Tech Rebound Lifts All Three Major Indexes; Dow Posts Weekly Gain of Over 400 Points
Profile
Nicox S.A. is a French ophthalmology company developing treatments to maintain vision and improve ocular health. Nicox is headquartered in Sophia Antipolis, France, and its Chairman and CEO is Michele Garufi.
Nicox is listed on Euronext Paris and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. Its pipeline includes three programs in development, and it has two U.S. Food and Drug Administration approved products. Wikipedia
About NicOx SA
CEO-
Employees10
Founded1996
HeadquartersValbonne, Provence-Alpes-CĂ´te d'Azur, France
SectorBiotechnology
Websitenicox.com